Description

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity[1][2].—COVID-19-immunoregulation–C67H118N26O16.xC2HF3O2—-[1]Mellor H, et al. The extended protein kinase C superfamily. Biochem J. 1998 Jun 1;332 ( Pt 2):281-92.|[2]Nishizuka Y (1995). Protein kinase C and lipid signaling for sustained cellular responses” (abstract). FASEB J. 9 (7): 484–96.—-1543.82 (free acid)—-OC(C(F)(F)F)=O.CC(C)[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](C)NC(CNC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–H2O–PKC—-Epigenetics;TGF-beta/Smad–Peptides